Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2025 08:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for...
September 26, 2024 08:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment...
July 24, 2024 10:23 ET | Source: Research and Markets

U.S. Biodefense Industry Research 2024-2030: Focus on Anthrax, Small Pox, Botulism, & Radiation/Nuclear

Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. Biodefense Market Size, Share & Trends Analysis Report by Product (Anthrax, Small Pox, Botulism, Radiation/nuclear), and Segment Forecasts,...
May 18, 2023 06:03 ET | Source: Research and Markets

Biodefense Market Global Market Report 2023: Infectious Diseases Pose Mounting Threat to Global Health, Spurring Explosive Growth

Dublin, May 18, 2023 (GLOBE NEWSWIRE) -- The "Biodefense Market - Global Industry Analysis (2019 - 2022), Growth Trends, and Market Forecast (2023 - 2030)" report has been added to ...
September 26, 2022 16:12 ET | Source: Emergent BioSolutions

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA®...
May 16, 2022 06:32 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threatTransaction to be funded...
February 07, 2022 05:03 ET | Source: Research and Markets

Biodefense Industry Trends and Opportunities 2021-2025 - Insights Into Anthrax, Smallpox, Botulism, and Other Applications

Dublin, Feb. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Biodefense Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The global biodefense market is projected to grow by...
September 03, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile

Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weaponSupports the government’s continued efforts and long-term strategy to maintain...
June 03, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness

GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response...
January 30, 2019 04:09 ET | Source: Global Market Insights, Inc

Biodefense Market value to surpass $19 Billion by 2024: Global Market Insights, Inc.

Sellbyville, Delaware, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Canada biodefense market was valued at USD 349.3 million in 2017 and is expected to have considerable revenue size during the forecast...

Next Page keyboard_arrow_right